Princy Kumar

机构：Georgetown University, Georgetown University Medical Center, Hospital for Tropical Diseases · ORCID：0000-0002-5994-2727

发表论文 267 篇 · 总被引 13866 次 · h-index 51

代表论文

• Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study (2025 · The Lancet Infectious Diseases · 被引 13)
• High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence (2024 · Journal of Medical Virology · 被引 12)
• Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE (2026 · The Lancet HIV · 被引 2)
• Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials (2025 · BMC Infectious Diseases · 被引 2)
• IL-27 effects on HIVGag-specific CD4 and CD8 T cell function (2025 · Frontiers in Virology · 被引 2)
• Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial (2026 · The Lancet · 被引 1)